Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events.

Trial Profile

Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Heparin; Heparin
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Biomarker; Therapeutic Use
  • Acronyms ATOLL
  • Most Recent Events

    • 03 Jul 2015 Results published in the American Heart Journal.
    • 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2012 Tolerability outcomes (major bleeding complications) presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top